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Abstract
Left ventricular (LV) diastolic dysfunction (DD) and diastolic heart failure (HF), that is symptomatic
DD, are due to alterations of myocardial diastolic properties. These alterations involve relaxation
and/or filling and/or distensibility. Arterial hypertension associated to LV concentric remodelling is
the main determinant of DD but several other cardiac diseases, including myocardial ischemia, and
extra-cardiac pathologies involving the heart are other possible causes. In the majority of the
studies, isolated diastolic HF has been made equal to HF with preserved systolic function (= normal
ejection fraction) but the true definition of this condition needs a quantitative estimation of LV
diastolic properties. According to the position of the European Society of Cardiology and
subsequent research refinements the use of Doppler echocardiography (transmitral inflow and
pulmonary venous flow) and the new ultrasound tools has to be encouraged for diagnosis of DD.
In relation to uncertain definitions, both prevalence and prognosis of diastolic heart failure are very
variable. Despite an apparent lower death rate in comparison with LV systolic HF, long-term
follow-up (more than 5 years) show similar mortality between the two kinds of HF. Recent studies
performed by Doppler diastolic indexes have identified the prognostic power of both transmitral
E/A ratio < 1 (pattern of abnormal relaxation) and > 1.5 (restrictive patterns). The therapy of LV
DD and HF is not well established but ACE-inhibitors, angiotensin inhibitors, aldosterone
antagonists and β -blockers show potential beneficial effect on diastolic properties. Several trials,
completed or ongoing, have been planned to treat DD and diastolic HF.
Introduction
Heart failure (HF) is a clinical syndrome whose symptoms
and signs are due to increased extravascular water and
decreased tissue / organ perfusion. The definition of the
mechanisms inducing HF needs the measurement of both
left ventricular (LV) systolic and diastolic function since
HF may occur in patients with either normal or abnormal
LV ejection fraction (EF) [1].
Arterial hypertension is the most common risk factor for
HF in the general population and myocardial infarction,
LV hypertrophy (LVH) and valve heart disease represent
predictors of subsequent HF in hypertensive patients of
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both genders [2]. The progression of hypertensive cardio-
myopathy towards HF includes serial LV changes – LV
concentric remodelling and LVH – whose prognostic role
is recognized [3-5]. In presence of these LV geometric
abnormalities, deep modifications of LV diastolic proper-
ties occur. These modification are globally defined as LV
diastolic dysfunction (DD) and include alterations of
both relaxation and filling [6,7] which can precede altera-
tions of LV systolic function and be per se main determi-
nants of symptoms and signs of HF. Several other cardiac
pathologies as well as extra-cardiac diseases involving sec-
ondarily the left ventricle can also affect myocardial
diastolic properties and determine LV DD.
LV DD and diastolic HF, that is the symptomatic DD, rep-
resent clinical entities which can be described at different
levels, from the hystologic and ultrastructural features to
the clinic manifestations and diagnostic instrumental
findings, until the prognostic and therapeutic aspects. The
growing interest for DD and for diastolic HF has been
developed gradually in the last 10–15 years. It rises mainly
from the advancement of non invasive imaging tools,
above all Doppler echocardiography, which, to date,
allows easy and repeatable identification of LV diastolic
abnormalities, and by the growing impulse of pharmaceu-
tical industry, at constant search of new therapeutic appli-
cations. In relation to the increase of the average life and
the future projections which suggest HF as the most
important pathology of the new millennium, particularly
in the elderly population, it has to be understood how
diagnosis, prognosis and therapeutic management of DD
represent very attractive perspectives.
Physiology of diastole
Although in normal hearts the transition from contraction
to relaxation begins much more before LV end-systole,
i.e., at 16% to 20% of the ejection period [8,9] and even
prior to aortic valve opening when LV contractility is
severely impaired (9), the traditional definition of dias-
tole (in ancient Greek language the term διαστολε  means
"expansion"), includes the part of the cardiac cycle start-
ing at the aortic valve closure – when LV pressure falls
below aortic pressure – and finishing at the mitral valve
closure. A normal LV diastolic function may be clinically
defined as the capacity of the left ventricle to receive a LV
filling volume able in its turn to guarantee an adequate
stroke volume, operating at a low pressure regimen.
In merely descriptive terms, diastole can be divided in 4
phases [10]:
1. Isovolumetric relaxation, period occurring between the
end of LV systolic ejection (= aortic valve closure) and the
opening of the mitral valve, when LV pressure keeps going
its rapid fall while LV volume remains constant. This
period Is mainly attributed to the active LV relaxation,
with a lower, variable contribution of elastic recoil of the
contracted fibers;
2. LV rapid filling, which begins when LV pressure falls
below left atrial pressure and the mitral valve opens. Dur-
ing this period the blood has an acceleration which
achieves a maximal velocity, direct related to the magni-
tude of atrio-ventricular pressure, and stops when this gra-
dient ends. This period represents a complex interaction
between LV suction (= active relaxation) and visco-elastic
properties of the myocardium (= compliance);
3. diastasis, when left atrial and LV pressures are almost
equal and LV filling is essentially maintained by the flow
coming from pulmonary veins – with left atrium repre-
senting a passive conduit – with an amount depending of
LV pressure, function of LV "compliance".
4. atrial systole, which corresponds to left atrial contraction
and ends at the mitral valve closure. This period is mainly
influenced by LV compliance, but depends also by the
pericardial resistance, by the atrial force and by the atrio-
ventricular synchronicity (= ECG PR interval).
Cardiac catheterization allows to assess the pressure-vol-
ume relation along the overall cardiac cycle. Among the
various hemodynamic measurements, τ  (= time constant
of the isovolumic-pressure decline) and DP/DV ratio,
expression of LV end-diastolic myocardial stiffness, are
the main invasive measurements of LV diastolic function
[10]. On the other hand, Doppler recording of transmitral
and pulmonary venous flow measure flow velocities and
time intervals, whose variations occur in relation to anal-
ogous variations of left atrial and LV pressures [11,12].
Thus, Doppler parameters provide important information
about dynamics of LV filling and LV diastolic properties
during disease evolution or improvement [13].
Ultrastructural features of diastolic dysfunction
The extracellular matrix (ECM), corresponding to fibrillar
collagen, is an important structure for processes of both
myocardial contraction and relaxation. It facilities the
arrangement of the cardiomyocites into the most suitable
allocation for the development of force and shortening,
giving a substantial support to the maintenance of an
effective myocardial performance [14]. The myocardial
remodelling is accompanied by changes of myocardial
cell factors but also of the ECM where fibroblast prolifer-
ation, alteration of the collagen network and increase in
interstitial and perivascular collagen are strongly pro-
moted by renin-angiotensin-aldosterone system [15].
ECM has, therefore, to be considered a dynamic entity
playing a fundamental role into the myocardial adapta-
tion to physiologic and pathologic stress [14]. ECMCardiovascular Ultrasound 2005, 3:9 http://www.cardiovascularultrasound.com/content/3/1/9
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undergoes an intense turnover, due to balanced action of
metalloproteases, proteolytic enzymes activated by sev-
eral factors including also BNP, and tissue inhibitors
counterbalancing the activity of metalloproteases [16].
Thus, if the collagen destruction alters both geometry and
function of contractile myocardium throughout an up-
regulation of metalloproteases, on the other hand myo-
cardial fibrosis occurs because of an imbalance where col-
lagen deposition prevails over its degradation. According
to the ultrastructural view, we can hypothesize two oppo-
site pathologic conditions: the first one, when the colla-
gen loss, e.g, after acute myocardial infarction, deprives
myocardium of its indispensable support structure, thus
inducing a reduction of myocardial systolic function; the
second one, when the accumulation of the same collagen,
main component of myocardial fibrosis, determines both
systolic and diastolic myocardial dysfunction. In this con-
text not only the total amount of collagen is main deter-
minant of LV diastolic stiffness but also distribution,
configuration, disorganization of collagen fibers (cross-
hatching), and ratio of collagen type I to collagen type III
play an important role [14].
Clinical, hemodynamic and diagnostic and 
aspects of diastolic dysfunction
In the clinical setting the coexistence of systolic and
diastolic dysfunction in patients with symptomatic HF
occurs very often. In fact, LV stiffness (or compliance) is
related to the length of myocardial fibers, reflecting in its
turn on LV end-diastolic dimensions. LV diastolic func-
tion, through the influence on left atrial and capillary
wedge pressures, determines the onset of symptom in
patients with prevalent LV systolic dysfunction too.
In parallel to the ultra-structural level, the clinical progres-
sion of HF may follow two different routes. In the first
one, as it happens after acute myocardial infarction, post-
infarction LV dilation (= remodelling) leads to systolic dys-
function and/or systolic heart failure. In the second one, LV
structural abnormalities (= LV concentric geometry)
induce functional alterations of DD. When diastolic dys-
function becomes symptomatic – that is, when dyspnoea
occurs – diastolic heart failure rises.
The majority of patients affected by isolated diastolic HF
show symptoms not at rest but in relation to stress condi-
tions (II NYHA class). Symptoms can be induced or wors-
ened by, firstly, physical exercise but also by events as
anaemia, fever, tachycardia and some systemic patholo-
gies. In particular, tachycardia reduces the time needed for
global LV filling, thus inducing an increase of left atrial
pressure and consequent appearance of dyspnoea,
because of accumulation of pulmonary extravascular
water.
The diagnosis of HF can be performed obviously by the
simple clinical examination but the identification of the
diastolic origin needs an instrumental assessment. In fact,
the objective examination of patients with diastolic HF
allows to notice the same signs occurring for systolic HF
and even the thoracic X-ray can not be useful to distin-
guish the two entities. ECG can show signs of LVH, due to
hypertensive cardiomyopathy or other causes. DD may be
asymptomatic and, therefore, identified occasionally dur-
ing a Doppler echocardiographic examination (Figure 1).
The diagnostic importance of this tool rises from the high
feasibility of transmitral Doppler indexes of diastolic
function, shown even in studies on population [17], such
to be suitable and accurate also for serial evaluations over
time. To date, standard Doppler indexes may be effica-
ciously supported by the evaluation of pulmonary venous
flow [18] (Figure 2) and by new ultrasound technologies
as Tissue Doppler [19] (Figure 3) and color M-mode
derived flow propagation rate [20]. The application of
maneuvers (Valsalva, leg lifting) [21,22] to Doppler trans-
mitral pattern and/or different combination of standard
transmitral Doppler with the new tools (ratio between
atrial reverse velocity duration and transmitral A velocity
duration, ratio between transmitral E peak velocity and
Tissue Doppler derived Em of the mitral annulus or flow
propagation velocity [Vp]) are sufficiently reliable to pre-
dict capillary wedge pressure and to distinguish accurately
variations of LV end-diastolic pressure [23,24]. Some of
these tools are effective even in particular situations as
sinus tachycardia [25] and atrial fibrillation [26] while the
pulmonary venous flow or the Valsalva maneuver applied
to transmitral inflow has to be preferred in the case of
mitral valve prosthesis and aortic valve regurgitation [27].
In addition, Tissue Doppler is also able to "read" the per-
centage of myocardial fibrosis [28], primum movens of DD.
Alone or, better, combined together, these tools permits
to recognize normal diastole as well as to diagnose and
follow the progression of DD from the pattern of abnor-
mal relaxation (grade I of DD) until pseudonormal (grade
II) and restrictive (grade III-IV) patterns (Table 1).
By the hemodynamic point of view, the differences
between diastolic and systolic HF are expressed by the
pressure-volume loop (Figure 4) [29]. When systolic HF
occurs, increased LV filling pressures correspond to
increased LV volumes, with a displacement of the loop
upon and at right. In the case of diastolic HF, the increase
of LV filling pressures occur in the presence of normal or
even reduced LV volumes, thus moving the loop up and
to the left. It is obvious that in the more advanced stages
of HF, diastolic and systolic dysfunction coexist.
Determinants of diastolic dysfunction
LV DD develops in several cardiac diseases [30] as well as
in extra-cardiac pathologies involving the heartCardiovascular Ultrasound 2005, 3:9 http://www.cardiovascularultrasound.com/content/3/1/9
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(accumulation diseases as amyloidosis, thyroid disorders,
acromegaly and others) [31,32] and in myocardial
ischemia due to coronary artery stenosis or even to iso-
lated dysfunction of coronary microcirculation [33].
However, the main cause of DD is arterial hypertension
[5-7]. Overweight and obesity, often coexisting with the
same hypertension, deeply affects LV diastolic function,
forcing the left ventricle to a working overload [34]. In this
view, DD represents one of the cardiac consequences of
pluri-metabolic syndrome, where arterial hypertension,
obesity, glucose intolerance and hypertrygliceridemia
cohabit in the same subject, having their common matrix
in the insulin resistance. High levels of insulin resistance,
often evident in arterial hypertension [35], are positively
associated with the prolongation of isovolumic relaxation
time, independent of LV geometric changes and of
increased afterload [36]. The alteration of diastolic isovo-
lumic relaxation is probably due to an increment of intra-
cellular calcium, which has been observed in insulin
resistant hypertensives and is induced in its turn by an
abnormal re-uptake of calcium by sarcoplasmic reticulum
[37]. Also the hormones produced by adipose tissue, as
leptin – involved into the control of body weight through-
out food absorption and energy-giving cost – negatively
affects LV diastolic function [38]. The association of arte-
rial hypertension and diabetes mellitus worsens furher
Doppler indexes of LV diastolic function as shown into
the population of the Strong Heart Study [39].
It is controversial whether LV DD is necessarily accompa-
nied on the development of LVH or rises up independent
of it [5-7,40-43]. It is true that DD is a direct sequence of
In the left screen, methodological outline for the measurement of Doppler transmitral indexes of diastolic function Figure 1
In the left screen, methodological outline for the measurement of Doppler transmitral indexes of diastolic function. In the right 
screen, normal diastolic pattern (upper part) and pattern of abnormal relaxation (lower part). A = atrial velocity (m/s), DT = 
deceleration time of E velocity (ms), E = early diastolic velocity (cm/s), IVRT = isovolumic relaxation time (ms)
IVRT
E
A
DT Università Federico II Cardioangiologia
E
A
A
E
E
A
ms
m/sCardiovascular Ultrasound 2005, 3:9 http://www.cardiovascularultrasound.com/content/3/1/9
Page 5 of 14
(page number not for citation purposes)
pressure overload, associated to elevated 24-hour blood
pressure [40] and even more to the increment of night-
time diastolic blood pressure [43]. Recent studies point
out that the diastolic abnormalities of hypertensive
patients are related to inappropriately high levels of LV
mass, disproportionate to the hemodynamic load pre-
dicted by the individual body size and cardiac load, more
than to the values of LV mass which traditionally define
LVH [44]. Inappropriately high LV mass is a potent predic-
tor of cardiovascular risk in hypertensive patients, in pres-
ence as in absence of clear cut LVH [45]. The concept of
DD onset preceding the appearance of LVH is consistent
with the observation that BNP, whose levels grow gradu-
ally with the progression of DD grading (from abnormal
relaxation until restrictive Doppler patterns) [46], are
increased in patients with diastolic HF independent of the
magnitude of LV mass [47]. Even a new ultrasound tech-
nology as Tissue Doppler supports the hypothesis of an
early evidence of DD in hypertensive heart: myocardial
DD (= Em/Am ratio < 1 at the level of multiple LV walls in
the apical views) is detectable before the appearance of
the abnormalities involving LV transmitral inflow and is
uniform in non hypertrophic patients while it becomes
prominent at the septum in presence of overt LVH [48].
Table 2 reports the differential characteristics involving in
the meantime the myocardial ultra-structure and LV
geometry in systolic and diastolic HF: it is clear that
diastolic HF is associated to both increase of collagen
amount and LV concentric geometry [49]. This concept is
further supported by the HyperGEN study where delayed
In the left screen, methodological outline for the measurement of pulmonary veins flow Figure 2
In the left screen, methodological outline for the measurement of pulmonary veins flow. In the right screen, normal pulmonary 
veins flow pattern (upper part) and pattern of abnormal relaxation (lower part).
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LV relaxation is independently associated with concentric
LV geometry in 1384 hypertensive participants including
obese and diabetic patients [50].
Definition and classification criteria for diastolic 
HF
The evidence of acute HF in absence of overt LV systolic
dysfunction rises by the experience of Gandhi and cow-
orkers [51]: thirty-height hypertensive patients affected by
pulmonary oedema, undergoing echocardiographic
examination during the acute episode and after clinical
stabilization respectively (1–3 day after), did not show
significant variations of LV EF (50 ± 15% and 50 ± 13%
respectively, NS) and of wall motion score index between
the two examinations. This clinical condition, defined as
heart failure with preserved systolic function or, better,
with normal EF, has been made equal to isolated diasto-
lic heart failure. A truly correct definition of this clinical
entity should, however, be done on the grounds of direct
estimation of LV diastolic function and establishment of
reference normal values. Strong controversy has been
developed in the previous years about this issue, with
opposite scientific positions. The American point of view,
corresponding to the Framingham Heart Study investiga-
tors, has sustained the concept that diastolic HF is "defi-
nite" only when an invasive hemodynamic assessment
In the left screen, methodological outline for the measurement of Tissue Doppler indexes Figure 3
In the left screen, methodological outline for the measurement of Tissue Doppler indexes. In the right screen, normal myocar-
dial diastolic pattern (upper part) and pattern of abnormal myocardial relaxation (lower part). Am = myocardial atrial velocity 
(cm/s), CTm = myocardial contraction time (ms), DTm = myocardial deceleration time of Em(ms), Em = myocardial early-diasto-
lic velocity (cm/s), PCTm = myocardial pre-contraction time (ms), RTm = myocardial relaxation time (ms).
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shows diastolic alterations in the temporal proximity of
the acute episode [52]. On the other hand, the European
point of view (European Group on Diastolic Heart Fail-
ure) has defined diastolic HF according to criteria includ-
ing clinical examination, echocardiographic assessment
(normal EF) and Doppler indexes (derived by both trans-
mitral inflow e pulmonary veins flow), whose normal
partition values are referred for age ranges [53] (Table 3).
Despite the obvious superiority of the invasive technique
[54], it has to be taken into account that the need of car-
diac catheterization for establishing a definite diagnosis of
diastolic HF raises practical and even ethical issues. Prac-
tical issues are related to the low priority such examina-
tion would have in a cath-lab overloaded by coronary
procedures and to the poor interest of hemodynamists in
the assessment of indexes of LV diastolic function. Ethical
concern lies upon the fact that the present reliance on
echo-Doppler examination of LV diastolic function makes
cardiac catheterization an useless invasive procedure to
this end, except very particular cases. Moreover, if it is true
that the prevalence of abnormal Doppler indexes (from
38% of isovolumic relaxation time to 64% for decelera-
tion time) is much lower to that showed by the more reli-
able invasive measurements (92 % for LV end-diastolic
pressure and 79 % for τ ) [55], is also true that this can be,
at least partially, due to the confounding influence of
physiologic variables as age [56] and heart rate [57]. In
this view, reference normal values of Doppler indexes of
LV diastolic function should be done considering ranges
of both age and heart rate. It is now current opinion that
the diagnosis of diastolic HF can be made even without
measurement of diastolic function if three criteria are
present: 1) symptoms and signs of HF (Framingham crite-
ria), 2) LV EF> 50%, and 3) ability to rule out mitral sten-
osis, pericardial disease, and non cardiac causes of
dyspnoea, oedema and fatigue [58]. Recent evidences fur-
ther sustain the definite role of Doppler echocardiography
to diagnose diastolic HF [59,60].
To date, however, no certain definition of diastolic HF
exists and the recognition of its existence is not unani-
mously accepted [49]. Studies performed by both stand-
ard Doppler echocardiography [61] and Tissue Doppler
[62,63] demonstrated how sub-clinic alterations of myo-
cardial systolic function are already overt in diastolic HF.
Because of the use of LV EF is a rather insensitive indicator
Table 1: Doppler echocardiographic patterns of current echocardiographic tools in relation to the grading of LV diastolic dysfunction
Parameter Normal pattern Pattern of abnormal 
relaxation (Grade I)
Pseudonormal pattern 
(Grade II)
Restrictive patterns 
(Grades III-IV)
E/A >1 <1 1 – 2 ≥ 2
DT (ms) 160 – 210 >220 150 – 200 <150
IVRT (ms) 70 – 90 >95 60 – 95 <60
S/D 1.3 – 1.5 1.6 – 2.0 <1 0.40 – 0.60
AR (m/sec) 0.22 – 0.32 0.21 – 0.28 ≥ 0.35 ≥ 0.25
Em (cm/sec) >8 <8 <8 <5
V p  ( c m / s e c ) > 5 5< 4 5< 4 5< 3 5
E/Em < 8 > 16
E/Vp > 2.5
AR = Atrial retrograde velocity, DT = Deceleration time, E/A = Transmitral E/A ratio, E/Em = Transmitral early diastolic velocity to myocardial early 
diastolic velocity of lateral mitral annulus by Tissue Doppler, Em = myocardial early diastolic velocity by Tissue Doppler at lateral mitral annulus, 
IVRT = Isovolumic relaxation time, = Systolic velocity to diastolic velocity ratio by pulmonary veins assessment, Vp = Velocity propagation
Table 2: Differential characteristics of LV geometry between systolic and diastolic HF (modified from Zile MR [49]).
Characteristic Systolic HF Diastolic HF
LV volume ↑
↑↑
N (o ↓ )
LV mass ↑↑
LV geometry Eccentric Concentric
Cardiomyocites ↑  Length ↑  Diameter
Extracellular Matrix ↓ (o ↑  o N) Collagen ↑↑  Collagen
HF = heart failure, LV = left ventricular, N = normalCardiovascular Ultrasound 2005, 3:9 http://www.cardiovascularultrasound.com/content/3/1/9
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Pressure-volume loops in systolic HF (upper part) and diastolic HF (lower part) Figure 4
Pressure-volume loops in systolic HF (upper part) and diastolic HF (lower part). The continuous black line refers to normal, 
the interrupted red line to the pathologic condition.
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of true LV myocardial contractility, the assessment of LV
long-axis function by the simple M-mode of the mitral lat-
eral annulus could help to identify initial LV systolic dys-
function [64]. Finally, it has also to be taken into account
how concomitant variables, including obesity, chronic
obstructive lung disease and even myocardial ischemia,
can be confounding factors leading to "false" diagnosis of
diastolic HF, particularly in the elderly population [65].
Prevalence of diastolic HF
The studies performed until now have assessed above all
the prevalence of HF with normal EF, using standard
echocardiography without Doppler. In a first meta-analy-
sis of 1995, the investigators of the Framingham Heart
Study [66] showed wide variability in the prevalence of
this kind of HF (range = 13–74%) while a subsequent
study involving the Framingham offspring cohort pointed
out a 51% prevalence of overall HF [67]. Very recently,
Hogg et al collected ten "cross-sectional" studies on pop-
ulation, in the United States as in several European coun-
tries, and found very high variability of HF with normal
EF. The explanation of this variability is related mostly to
different age and gender of participants. It has to be con-
sidered that this kind of HF is particularly frequent in the
elderly population, occurs more often in the female gen-
der and is associated much more with arterial hyperten-
sion and atrial fibrillation than to coronary heart disease
[68]. The data collected between 1995 and 1999 from Ital-
ian Network on Congestive Heart Failure (IN-CHF) are
strongly consistent with these results [69]. The choice of
different cut-off points for normal LV EF can be an addi-
tional reason of variability for the prevalence of diastolic
HF in the above mentioned studies.
Prognosis of diastolic heart failure
Great heterogeneity exists also for results in prognosis of
diastolic HF. By the Framingham meta-analysis the
annual mortality varies from 1.3% to 17.5% [66]. This
wide variability depends by several factors including first
of all, the modality used to classify this kind of HF –
mostly according to the evidence of normal EF – but also
age and follow-up duration. In a study by registry on 1291
hospitalized patients (70) the mortality was lower in
patients with EF ≥  50% than in those with EF ≤  39% (OR
= 0.69 95% CI 0.49–0.98, p = 0.04) . The Framingham off-
spring cohort informed that the rate of death after 5 years
is 68% in patients with HF and normal EF in comparison
with 82% of systolic HF, with a mortality, however, four
times greater than that presented by healthy subjects [67].
Although Senni et al (71) did not find difference of
mortality between the two kinds of HF in a 4-year follow-
up of a population with mean age of 78 years, the analysis
of Hogg and coworkers, assembling the results of recent
cohort studies performed on patients hospitalized for HF,
noticed how the percentage of mortality for patients with
HF and normal EF, mild during the first year and half,
becomes similar to that of systolic HF after 5–6 years of
follow-up (68). It is worthy of note the recent study of
Badano and coworkers who, using the ESC criteria to
identify diastolic HF in 179 patients hospitalized with HF,
do not observe significant difference in 6-month mortality
in comparison with patients having prevalent LV systolic
dysfunction [72].
Two important studied have finally pointed out the prog-
nostic value of Doppler indexes of LV diastolic function
and in particular of transmitral E/A ratio [73,74]. The first
one, the PIUMA study [73], evidenced that the pattern of
abnormal relaxation (= E/A ratio lower than that
predicted individually by age and heart rate) increases the
risk of cardiovascular events (odds ratio 1.57, 95% CI 1.1-
2,18, p < 0.01) in a population of 1839 hypertensive
patients during a 11 years follow-up. This prognostic
value is independent of the effect of LV mass and even of
ambulatory 24-hour blood pressure. In the second one,
the Strong Heart Study [74], by a 3-year follow-up on a
population of 3008 American Indians, a transmitral E/A
ratio < 0.6 (= likewise pattern of abnormal relaxation) is
associated to a doubled increase of mortality risk – despite
not independent of other covariates – and an E/A ratio >
1.5 (= likewise pattern pseudonormal / restrictive) is asso-
ciated to an threefold increase of cardiac mortality, which
is also independent of several confounders including
LVH. This result is consistent with the findings of the
Framingham Heart Study, where an "U" relation between
transmitral A velocity and risk of atrial fibrillation is
Table 3: Criteria for diastolic HF according to the European Society of Cardiology (53).
Signs and symptoms of HF Effort dyspnoea, Hortopnoea, III-IV tones, Pulmonary rales
Normal or mildly reduced LV systolic function EF ≥  45 % e LVIDDi > 3.2 cm·m -2
Evidence of abnormalities LV of relaxation/filling and/or distensibility IVRT <30 years > 92 ms, 30–50 years > 100 ms, >50 years > 105 msc
E/A<1 + DT>220 ms + S/D<1.5 <50 years
E/A<0.5 + DT>280 msec + S/S>2.5 >-50 years
DT = deceleration time of E velocity, E/A = ratio of early diastolic velocity to atrial velocity, EF = ejection fraction, HF = heart failure, IVRT = 
isovolumic relaxation time, LV = left ventricular, LVIDDi = left ventricular internal diastolic diameter index, S/D = ratio of systolic to diastolic 
velocity of venous pulmonary veinsCardiovascular Ultrasound 2005, 3:9 http://www.cardiovascularultrasound.com/content/3/1/9
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detectable, and the arrhythmia appears independently
associated with both A velocity increase (= abnormal
relaxation) and E/A ratio increase (pattern pseudonormal
/ restrictive) [75]. These two studies, in particular the
Strong Heart Study by data on mortality, are very consist-
ent with the physiopathologic point of view of the Mayo
Clinic investigators, who created an ingenious classifica-
tion of Doppler-.derived DD some years ago [21]. In this
classification, the pattern of abnormal relaxation (grade I
of DD) and both reversible and non reversible restrictive
patterns (grade III and IV respectively) are at opposite
sides in the clinical progression towards the end stages of
HF while the pseudo-normal pattern has an intermediate,
but clinically crucial, position (Figure 5). In view of these
findings and combining the value of the prognostic stud-
ies, we can suppose that the relatively long time (5–6
years) needed to assimilate the prognosis of diastolic HF
to that of systolic HF depends mainly by the transition
from the initial grade of DD, when the pattern of abnor-
mal relaxation prevails and dyspnoea is overt only during
exercise, to the more advanced stages, when the high LV
end-diastolic pressure is associated to "end-stage" HF.
Therapy of DD and diastolic HF
The objectives of the therapy for LV DD include the
improvement of hemodynamic conditions, concerning
both preload and afterload. The volume overload, such to
induce episodes of acute HF, can be prevented or reduced
by hypo-saline diet or also by a moderate diuretic
administration.
Results of overall and cardiac mortality in relation to transmitral E/A ratio in the Strong Heart Study [74] (upper panel)) and  classification of DD grades (I-IV) according to Mayo Clinic suggestions [21] (lower panel) Figure 5
Results of overall and cardiac mortality in relation to transmitral E/A ratio in the Strong Heart Study [74] (upper panel)) and 
classification of DD grades (I-IV) according to Mayo Clinic suggestions [21] (lower panel). It can be observed a parallel behav-
iour between clinic progression and prognostic value of different grade of DD: the increment of mortality in Strong Heart 
Study has an "U" behavior, where E/A ratio <0.6 (grade I of DD) and >1.5 (grades II, III, IV) are both main predictors of mortal-
ity DD = diastolic dysfunction, NYHA = New York Heart Association, MAP = mean atrial pressure
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Conceptually, both ACE-inhibitors and angiotensin-
inhibitors can exert a beneficial effect on DD, since they
reduce both afterload and preload, induce regression of
LVH and decrease of myocardial interstitial fibrosis [70].
Also the aldosterone antagonists, as sprironalattone [76]
and canrenone [77], able to reduce the myocardial fibro-
sis, can be suitable to this aim.
When DD is overt, it is also important to control heart rate
and avoid tachycardia. β -blockers, and, with a lower
extent, calcium antagonist verapamile, can be particularly
useful. Lower heart rate induces prolongation of LV filling
time, allowing to counterbalance the resistance to the
diastolic inflow of a stiffened left ventricle. Last genera-
tion  β -blockers (carvedilol, nebivolol), provided of
vasodilation activity, could be particularly indicated for
the management of DD. A recent study has tested the abil-
ity of nebivolol on 26 patients affected by HF and normal
EF, in comparison with the traditional atenolol, combin-
ing both invasive hemodynamic and Doppler echocardi-
ographic assessment [78]. After six-month therapy,
nebivolol much more than atenolol induced increase of
both E/A ratio (from 0.79 ± 0.13 a 0.91 ± 0.11) from 0.84
± 0.12 a 0.89 ± 0.15) (p < 0.004) and cardiac index and
reduction of "wedge" pressures, both at rest and during
exercise.
On these grounds, pharmaceutical industry has planned
clinical trias to evaluate the prognostic impact of several
drugs on diastolic HF. Indeed, the trials completed to date
have been disappointing. The CHARM-2 (= Candesartan
in Heart Failure – Assessment of Reduction in Mortality)
[79] did not evidenced significant improvement of all-
cause mortality, of cardiovascular mortality and of hospi-
talization rate for HF in the sub-set of patients with pre-
served systolic function, but the follow-up (37.7 months)
was probably too short to verify the effects. Into SWEDIC
(= Swedish Doppler-Echocardiographic study) [80],
carvedilol, inducing a positive influence on transmitral E/
A ratio in patients with heart rate > 71 bpm but not in
those with HR < 71 bpm, did not exert any effects on the
events. Among ongoing trials, the analysis of SENIORS (=
Study of the Effects of Nebivolol Intervention on
Outcomes and Rehospitalisation in Seniors with heart
failure) [81] has not yet performed in the sub-set of
patients with normal EF. PEP-CHF (perindopril versus
placebo), I-Preserve (Irbesartan versus placebo) study and
Hong Kong (rampiril, irbesartan, placebo) study have not
completed to date [82].
New therapeutic fields for HF will be opened in view of
the associations observed between the state of coronary
microcirculation and LV diastolic function [33]. The
beneficial effect of ACE-inhibitors on coronary flow
reserve, reliable marker of coronary microcirculation
function when stenosis of epicardial coronary arteries are
not detectable , has been documented in relation to both
blood pressure fall and reduction of LV mass. It has
recently shown an improvement of transthoracic Dop-
pler-derived coronary flow reserve after only 4-week anti-
hypertensive nebivolol therapy, in relation to its endothe-
lium-mediated vasodilation activity [85]. It has to hypoth-
esize that the a restored function of the coronary
microcirculation could be useful even for the improve-
ment of DD in hypertensive heart [83,84].
Conclusive implications
DD and diastolic HF are common entities in the clinical
practice, particularly in hypertensive population. The
diagnosis of diastolic HF can be considered in the pres-
ence of the signs of HF and normal EF (50% or more) but
it should be usually supported by a Doppler examination.
Diastolic HF is associated to four-fold increase mortality.
If it is true that the mortality expectation is lower than in
patients with systolic HF, it is even true that this difference
has a trend to be blunted during long-term follow-up,
with possible overlapping after 5.5 years or more. The
therapeutic management of diastolic HF is, at least par-
tially, empirical and several studies, ongoing or com-
pleted, have been planned to test the effects of ACE-
inhibitors, angiotensin-inhibitors and β -blockers. The
prevention of diastolic HF may be obtained by a better
control of blood pressure values and of concomitant risk
factors in hypertensive patients.
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